Delivery Order SPE2DB24D2106-SPE2DB26FATXJ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,678.00 to DMS Pharmaceutical Group Inc. on September 17, 2025, for the supply of Telmisartan 40 mg tablets (30-count units). This firm fixed-price delivery order, which must be completed by September 18, 2025, was issued without a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge location. The...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,367.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Telmisartan-HCTZ 80-12.5 mg tablets in unit dose packaging (30-count). The award was issued on August 12, 2025, with an ultimate completion date of August 13, 2025, and does not utilize a set-aside designation. Performance will take place in Conshohocken, Pennsylvania. This delivery order is issued...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,135.44 firm fixed-price delivery order is for the supply of Telmisartan 20 mg tablets and does not have a set-aside designation. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a firm fixed-price delivery order ceiling value of $4,541.76 and covers the supply of Telmisartan 20 mg tablets to fulfill the recurring pharmaceutical needs of military health facilities. DMS Pharmaceutical Group holds a larger indefinite-delivery contract (IDC) with the DLA under the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $1,950.22 by the Defense Logistics Agency (DLA) on August 22, 2025. The delivery order, issued under DLA's larger Indefinite Delivery Contract (SPE2DB program) valued at $499.999 billion and valid through November 2026, calls for the supply of Telmisartan-HCTZ 80-12.5 mg tablets in unit dose packaging (30 count)....
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,892.40, is for the delivery of Telmisartan 20 mg tablets over a term ending on February 2, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999 and running through...
- The Defense Logistics Agency awarded a delivery order valued at $1,770.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order, issued on October 21, 2025, represents a firm fixed-price purchase of pharmaceutical products and medical consumables under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The award carries no set-aside designation, demonstrating DMS...
- This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,671.69 firm fixed-price delivery order is for the provision of Telmisartan 40 mg tablets to support the recurring pharmaceutical supply needs of U.S. military healthcare facilities. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $30,173.10 by the Defense Logistics Agency's Medical Supply Chain division on October 20, 2025. This firm fixed-price delivery order represents one of numerous awards issued to DMS Pharmaceutical Group under its broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract, which carries a $500...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) under its SPE2DB program. The award has a ceiling value of $9,210.24 and covers the delivery of 4554944974 - Telmisartan 40 mg Tablets 30s to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB26FATXJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,523.54 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Telmisartan 20 mg tablets (30-count units). The award, issued on October 21, 2025, with an ultimate completion date of October 22, 2025, utilizes a firm fixed-price contract structure with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy that authorizes DLA to procure a full range of pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, demonstrating substantial contracting activity with the Defense Logistics Agency's Medical Supply Chain division. The company's PPV-G GEN V prime vendor contract, awarded on November 13, 2025, carries a ceiling value of $499.999 billion with an ultimate completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. This contract positions DMS Pharmaceutical Group to fulfill diverse and specialized pharmaceutical requirements for military healthcare facilities worldwide, supporting the Department of Defense's mission to maintain adequate medical supply inventories across its global healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 10/21/25 |